|| List of recent Peptide-related patents
|Identification of related peptides for mass spectrometry processing|
A method of identifying a related peak set from ms1 spectra data is provided. An intensity peak is selected from ms1 spectra data generated for a sample by a tandem mass spectrometer.
|Production of saturated fatty alcohols from engineered microorganisms|
Recombinant bacterial microorganisms are provided which comprise heterologous fatty acyl reductases (“far”) polypeptides wherein said microorganisms have been engineered to produce increased amounts of saturated fatty alcohols and methods of making saturated fatty alcohols using the recombinant bacterial microorganisms.. .
|Recombinant nel-like (nell) protein production|
The present invention provides a method and system for producing a nell protein. The method and system comprise a cell encoding a nell protein or peptide and a non-insect secretory signal peptide..
|Assembly of bispecific antibodies|
Described herein are methods for the efficient production of a heteromultimeric protein, such as a bispecific antibody. Heteromultimeric proteins may be capable of specifically binding to more than one target molecule or different epitopes on a single target molecule.
|Tyrosine, serine and threonine phosphorylation sites|
The invention discloses 155 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including aqua peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.. .
|Synthetic peptides for treatment of bacterial infections|
Disclosed are peptides and methods for the treatment of bacterial infections and associated inflammation. Effective doses and treatment protocols are disclosed..
|Methods and compositions for tumor vaccination and therapy|
The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. A cdr-2 antigen, hud antigen.
|Peptide agonists of glp-1 activity|
Novel peptide agonists of glp-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the glp-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable.
|Srm/mrm assay for the ephrin typa-a receptor 2 protein|
Specific peptides, and derived ionization characteristics of the peptides, from the ephrin type-a receptor 2 (epha2) protein are provided that are particularly advantageous for quantifying the epha2 protein directly in biological samples that have been fixed in formalin by the method of selected reaction monitoring (srm) mass spectrometry, or what can also be termed as multiple reaction monitoring (mrm) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
|Methods and products for reawakening retrocyclins|
Products and methods are provided for the restoring the endogenous expression of theta-defensins, such as retrocyclin-1, in mamallian cells. The present invention also includes products and methods for inhibiting sexually transmitted virus entry, e.g., hiv-1 virus entry, into a mammalian cell via, for example, administering to a subject an amount of a read-through mediating agent sufficient to induce exogenous expression of an amount of retrocyclin nonapeptides in the mammalian cell..
|Novel glp-1 receptor stabilizers and modulators|
Compounds that bind the glucagon-like peptide 1 (glp-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing glp-1 receptor in vitro for crystallization of the glp-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, gip receptor, glp-1 and glp-2 receptors, and pth receptor on their own or in the presence of receptor ligands such as gip (1-42), pth (1-34), glucagon (1-29), glp-2 (1-33), glp-1 (7-36), glp-1 (9-36), oxyntomodulin and exendin variants..
|Compositions and methods for modulating interaction between polypeptides|
The present invention is based, in part, on assays we conducted that revealed compounds that may be used to treat or prevent diseases characterized by an abnormal or undesirable association of one protein with another.. .
|Targeting the egfr-sglt1 interaction for cancer therapy|
A compound can destabilize a binding interaction between an epidermal growth factor receptor (egfr) and a sodium/glucose co-transporter 1 (sglt 1). In one embodiment, the compound is a peptide derived from the interacting domain of egfr.
|Gigaxonin fusion protein and methods for treating giant axonal neuropathy|
The present disclosure relates generally to fusion proteins including gigaxonin coupled to a cell penetrant peptide. These fusion proteins can be used to treat gan in a subject in need thereof.
|Stabilized peptide helices for inhibiting dimerization of chemokine c motif receptor 2 (ccr2)|
Peptide helices stabilized by backbone cyclization which are capable of inhibiting dimerization of the chemokine (c-c motif) receptor 2 (ccr2), as well as pharmaceutical compositions including such backbone cyclized peptide helices. Use of pharmaceutical compositions and peptide helices in treatment of multiple sclerosis (ms) and other diseases associated with ccr2 activation..
|Optineurin-derived polypeptides, their nucleic acids and uses thereof|
The invention relates to optineurin-derived polypeptide(s) consisting of a polypeptidic sequence disclosed in seq id no2, which represents the portion of the wild-type human optineurin protein sequence from its amino-acid residue 131 to its amino-acid residue 297, or having a polypeptidic sequence encompassing the polypeptidic sequence disclosed in seq id no2, or having a polypeptidic sequence derived from the polypeptidic sequence disclosed in seq id no2 to the exclusion of the wild-type optineurin protein. The polypeptide(s) of the invention retain one, any combination of two, or three of the following functional properties: the capacity to bind rab8 protein, when the latter are associated with the golgi apparatus of a cell, the capacity to bind mypt1 protein, when said protein is engaged in a myosin-phosphatase (mp) complex, the capacity to be phosphorylated by plk1.
|Polypeptides targeting glycosylated muc2 proteins, methods of synthesis, their nucleic acids and uses thereof|
The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence p1(xa)p3(xb)p5(xc)p6(xd)p7 (seq id no: 1), presenting specific patterns. The polypeptides of the invention target glycosylated muc2 proteins.
|Polypeptide for the protection against heart ischemia-reperfusion injury|
A peptide of the formula r1-nh-haegtftsdvssylegqaakefiawlvk-conr2r3 wherein r=h or an organic compound comprising from 1 to 10 carbon atoms and r2 r3=independently h or an alkyl group of 1 to 4 carbon atoms; or certain analogues of said glp-1 peptide can be used for the treatment and prophylaxis of heart ischemia-reperfusion injury. .
|Glycosylated polypeptide and drug composition containing said polypeptide|
[problem] to provide a glycosylated polypeptide having an affinity to somatostatin receptors, and, compared to somatostatins, having improved in-blood stability. [solution] the glycosylated polypeptide is characterized by at least one amino acid in a somatostatin or an analog thereof being replaced with a glycosylated amino acid..
|Modified mini-hepcidin peptides and methods of using thereof|
Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.. .
|Glp-1 receptor agonist peptide gastrin conjugates|
The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.. .
|Tripeptide epoxy ketone protease inhibitors|
And pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease..
|Anti-inflammatory peptides and use thereof|
Anti-inflammatory peptides and pharmaceutical compositions including lysine, alanine, leucine and/or valine for treating inflammatory conditions and uses thereof. Anti-inflammatory peptides for treating ige-mediated allergies and inflammatory conditions caused by a microbial infection including but not limited to sepsis..
|Stabilized subtilisin composition|
The conversion of a peptide aldehyde to a hydrosulfite adduct can be used to increase the aqueous solubility in the purification of the peptide aldehydes. Advantageously, this hydrosulfite adduct is itself effective as a subtilisin inhibitor and stabilizer and it can also stabilize a second enzyme if present.
|Assay buffer, compositions containing the same, and methods of using the same|
The invention relates to improved electrochemiluminescence assay methods for phosphorylated peptides or proteins employing phospho-specific antibodies and buffer compositions that are substantially free of inorganic phosphate.. .
|Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit|
Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.. .
|Method for finding bioactive peptides|
The present invention relates to a method for discovering bioactive peptides, and a use thereof. The present invention relates to a method for discovering a peptide which has an effect on tissue regeneration or a peptide which adheres to a biomaterial, by searching the smallest bioactive domain from a protein.
|Cell growth-promoting peptide and use thereof|
The pharmaceutical composition provided by the present invention comprises at least one pharmaceutically acceptable carrier, and an active ingredient including an artificially synthesized peptide comprises: (a) an amino acid sequence constituting a cell-penetrating peptide and (b) an amino acid sequence constituting the signal peptide in amyloid precursor protein (app) or an n-terminal partial amino acid sequence or c-terminal partial amino acid sequence from the amino acid sequence constituting that signal peptide.. .
|Desaturases and process for the production of polyunsaturated fatty acids in transgenic organisms|
The present invention relates to polynucleotides from cochliobolus heterostrophus c5, cyanothece sp. Ccy0110, mycocentrospora acerin and hyaloperonospora parasitica, which code for desaturases and which can be employed for the recombinant production of polyunsaturated fatty acids.
|Use of enzymes having silicase activity|
The present invention relates to the use of polypeptides having silicase activity for the modification or synthesis of silica, silicones and other silicium (iv) compounds. The present invention also relates to the use of polypeptides having silicase activity for the modification of glass, sand, asbestos, computer chips, glass wool, fiber glass, optical fibers and silicones, for the removal of sand from oil-sands, for the removal of asbestos, and for sandblasting..
An object of the present invention is to provide a means for producing an optically active tropic acid that is a compound useful as a synthetic raw material or an intermediate for pharmaceutical products and the like. The present invention provides a novel polypeptide having activity to (r)-selectively hydrolyze a racemic tropic acid amide, dna encoding the polypeptide, a vector containing the dna, a transformant prepared by transformation with the vector, and a method for producing an optically active carboxylic acid amide and an optically active carboxylic acid using them..
|Polypeptides having catalase activity and polynucleotides encoding same|
Provided are isolated polypeptides having catalase activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Polypeptides having xylanase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having xylanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Method for production of polypeptide|
The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses cysteine sulfinic acid decarboxylase and has a transferred dna encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide.
|Methods of diagnosing als|
The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent.
|Peptide marker for cancer diagnosis and cancer diagnosis method using the same|
The present invention relates to a peptide marker for cancer diagnosis and a cancer diagnosis method using the same, more precisely to a peptide marker for cancer diagnosis screened by the following steps: separating and concentrating glycoproteins including a certain glycan chain related to the occurrence of cancer; hydrolyzing the glycoproteins to obtain polypeptides; and quantitatively analyzing the polypeptides to identify certain polypeptides that can track quantitative changes in glycoproteins glycosylated in a specific manner by the occurrence of cancer, and to a cancer diagnosis method using the said peptide marker.. .
|Method for designing rna binding protein utilizing ppr motif, and use thereof|
A method for designing a protein capable of binding in an rna base selective manner or rna base sequence specific manner is provided. The protein of the present invention is a protein containing one or more of ppr motifs (preferably 2 to 14 ppr motifs) each consisting of a polypeptide of 30- to 38-amino acid length represented by the formula 1 (wherein helix a is a moiety of 12-amino acid length capable of forming an α-helix structure, and is represented by the formula 2, wherein, in the formula 2, a1 to a12 independently represent an amino acid; x does not exist, or is a moiety of 1- to 9-amino acid length; helix b is a moiety of 11- to 13-amino acid length capable of forming an α-helix structure; and l is a moiety of 2- to 7-amino acid length represented by the formula 3, wherein, in the formula 3, the amino acids are numbered “i” (-1), “ii” (-2), and so on from the c-terminus side, provided that liii to lvii may not exist), and combination of three amino acids a1, a4 and lii, or combination of two amino acids a4, and lii is a combination corresponding to a target rna base or base sequence..
|Method for detecting an infection by the hepatitis c virus|
The invention relates to a method of in-vitro detection of an infection with a hepatitis c virus (hcv) in a biological sample, comprising the simultaneous detection of the hcv capsid protein, and of an antibody directed against said capsid protein, said method using, for capturing the anti-capsid antibodies, a peptide comprising an antigenic fragment derived from the truncated hcv capsid. The invention also relates to the peptide for capturing the anti-capsid antibodies and the kits comprising it..
|Intestinal peptide targeting ligands|
Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed..
|Peptide pharmaceutical for oral delivery|
Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition.
|Growth factor anchoring type bone graft material, method for producing growth factor anchoring type bone graft material, kit for producing growth factor anchoring type bone graft material, and method for forming bone|
Provided is a growth factor anchoring type bone graft material, wherein a bone graft substrate exposing at least a collagen fiber is bound to a collagen-binding-site-containing growth factor which contains a growth factor receptor agonist peptide and a collagen-binding peptide. The same can be produced by mixing a bone graft substrate and a collagen-binding-site-containing growth factor which contains a growth factor receptor agonist peptide and a collagen-binding peptide, and is also superior in osteogenic ability..
|Dual delivery system for heterologous antigens|
Provided herein are recombinant listeria strains expressing a tumor-specific antigenic polypeptide and, optionally, an angiogenic polypeptide wherein a nucleic acid molecule encoding at least one of the polypeptides is operably integrated into the listeria genome in an open reading frame with a nucleic acid sequence encoding a pest-containing polypeptide, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.. .
|Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual|
The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the human immunodeficiency viruses (hiv) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41..
|Synthetic peptide-based marker vaccine and diagnostic system for effective control of porcine reproductive and respiratory syndrome (prrs)|
A peptide-based marker vaccine against porcine reproductive and respiratory syndrome (prrs) and a set of immunodiagnostic tests for the prevention, monitoring and control of porcine reproductive and respiratory syndrome virus (prrsv) are disclosed. Vaccine formulations according to various embodiments of the invention contain a mixture of peptides derived from prrsv gp2, gp3, gp4, or gp5 proteins; each peptide individually contains a b cell prrsv neutralizing/receptor binding epitope which is individually linked to an artificial t helper epitope for enhancement of the respective peptide's immunogenicity; and which can be supplemented with a mixture of peptides representing the t helper epitopes derived from the prrsv gp4, gp5, m and nucleocapsid proteins to provide cell mediated immunity.
|Suppressors of mature t cells|
Disclosed herein is a viral polypeptide and homologs thereof that inhibit an immune response, particularly the response of memory and effector cd4+ and cd8+ t cells.. .
|Utility of insulin-like 6 (insl6) for the treatment of autoimmune diseases|
The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (insl6) agent, such as an insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding insl6 poly peptide or variant or fragment thereof. Aspects of the present invention relate to use of insl6 agents to reduce t-regulatory (treg) cells in the subject and to reduce pro-inflammatory cytokines in a subject with an autoimmune disease such as a muscle autoimmune disease.
|Nanobodies against tumor necrosis factor-alpha|
The present invention relates to improved nanobodies™ against tumor necrosis factor-alpha (tnf-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such nanobodies. The invention also relates to nucleic acids encoding such nanobodies and polypeptides; to methods for preparing such nanobodies and polypeptides; to host cells expressing or capable of expressing such nanobodies or polypeptides; to compositions comprising such nanobodies, polypeptides, nucleic acids or host cells; and to uses of such nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes..
|Aspartyl-trna synthetase-fc conjugates|
The present invention provides aspartyl-trna synthetase and fc region conjugate polypeptides (drs-fc conjugates), such as drs-fc fusion proteins, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The drs-fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified drs polypeptides..
|Modified heat shock protein-antigenic peptide complex|
The present invention relates to methods for purifying immunogenic, prophylactically and therapeutically effective complexes of modified heat shock proteins noncovalently associated with antigenic peptides of cancer or infected cells. The claimed methods comprise the constructing of a nucleotide sequence encoding a secretable modified heat shock protein, expressing the sequence in an appropriate host cell, recovering the immunogenic complexes from the cell culture and the cells, and purifying the immunogenic complexes by affinity chromatography.
A new fusion protein which can specifically suppress the autoantibodies, which can effectively prevent or treat the autoimmune disease of autoantibody type, and which can be expressed in an amount sufficient for industrial production. A fusion protein, characterized in that, a protein (x) containing a site recognized by autoantibodies which are a cause of the autoimmune disease of autoantibody type is connected to a protein (a) containing a fragment of the antibody heavy chain constant region which exhibits the antibody-dependent cellular cytotoxicity with a linker peptide (l) consisting of one or more amino acid(s), wherein the protein (x), the linker peptide (l) and the protein (a) are connected in this order by means of peptide bond from n terminal to c terminal..
|Composition exhibiting a von willebrand factor (vwf) protease activity comprising a polypeptide chain with the amino acid sequence aaggilhlellv|
The invention relates to vwf cleaving entities having a molecular weight of 180 kd, 170 kd, 160 kd, 120 kd or 110 kd and an n-terminal amino acid sequence of aaggilhlellv, vwf cleaving complexes and methods for their production.. .
|Human skin equivalents expressing exogenous polypeptides|
The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides.
|Quil a fraction with low toxicity and use thereof|
Fraction a of quil a can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g.
|Method for patient selection|
The present invention relates to methods useful in the selection of cancer patients suitable for treatment with therapies directed at c-met. The method employs imaging agents which comprise 18f-radiolabelled c-met binding peptides suitable for positron emission tomography (pet) imaging in vivo.